Organization
BioCanRx
- Meetings this Parliament
- 8
- With MPs
- 2
- Since Nov 2021
- 8
- Active registrations
- 1
Most recent reported meeting: Sep 9, 2026.
Lobbying by BioCanRx: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (organization) In effect since May 20, 2026 Receives government funding
Filed by Stéphanie Michaud, President and CEO
Lobbyists
-
Kenneth Tam · Director, Strategic Communications and External Relations
Former public office holder
Formerly Communications Consultant, Peter Braid, MP, House of Commons (2008–2010)
- Stéphanie Michaud · President and CEO
Institutions they may lobby: Canadian Institutes of Health Research (CIHR), Employment and Social Development Canada (ESDC), Finance Canada (FIN), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), National Defence (DND), Natural Sciences and Engineering Research Council (NSERC), Prime Minister's Office (PMO), Privy Council Office (PCO), Senate of Canada
What they're lobbying on (1)Hide details
- Continued funding for BioCanRx's Immunotherapy Network from various government funding opportunities to derisk immunotherapies, support made-in-Canada biomanufacturing and clinical trials, and training in translational research and commercialization.
Registration 963471-384378-3. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Stéphanie Michaud · In-house (organization)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Kasondra White · Acting Director General, Innovation, Science and Economic Development Canada (ISED)
Continued funding for BioCanRx's Immunotherapy Network from various government funding opportunities to derisk immunotherapies, support made-in-Canada biomanufacturing and clinical trials, and training in translational research and commercialization. Read more
-
Reported by Stéphanie Michaud · In-house (organization)
- Salma Zahid · Chair of SRSR Committee
Continued funding for BioCanRx's Immunotherapy Network from various government funding opportunities to derisk immunotherapies, support made-in-Canada biomanufacturing and clinical trials, and training in translational research and commercialization. Read more
-
Reported by Stéphanie Michaud · In-house (organization)
- Paul Hébert · President, Canadian Institutes of Health Research (CIHR)
- Jeff Moore · Associate Vice-President, Canadian Institutes of Health Research (CIHR)
Continued funding for BioCanRx's Immunotherapy Network from various government funding opportunities to derisk immunotherapies, support made-in-Canada biomanufacturing and clinical trials, and training in translational research and commercialization. Read more
-
Reported by Stéphanie Michaud · In-house (organization)
- David MacFarlane · Director of Policy, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Continued funding for BioCanRx's Immunotherapy Network from various government funding opportunities to derisk immunotherapies, support made-in-Canada biomanufacturing and clinical trials, and training in translational research and commercialization. Read more
-
Reported by Stéphanie Michaud · In-house (organization)
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Continued funding for BioCanRx's Immunotherapy Network from various government funding opportunities to derisk immunotherapies, support made-in-Canada biomanufacturing and clinical trials, and training in translational research and commercialization. Read more
-
Reported by Stéphanie Michaud · In-house (organization)
- Nipun Vats · ADM, Innovation, Science and Economic Development Canada (ISED)
- Andrea Smith · A/Director General, Innovation, Science and Economic Development Canada (ISED)
Continued funding for BioCanRx's Immunotherapy Network from various government funding opportunities to derisk immunotherapies, support made-in-Canada biomanufacturing and clinical trials, and training in translational research and commercialization. Read more
-
Reported by Stéphanie Michaud · In-house (organization)
- justine Frame · Policy Advisory, Health Canada (HC)
- Jaeda Shilke · Regional Advisor, Health Canada (HC)
Continued funding for BioCanRx's Immunotherapy Network from various government funding opportunities to derisk immunotherapies, support made-in-Canada biomanufacturing and clinical trials, and training in translational research and commercialization. Read more
-
Reported by Stéphanie Michaud · In-house (organization)
- Tony Baldinelli · Member of Parliament
Continued funding for BioCanRx's Immunotherapy Network from various government funding opportunities to derisk immunotherapies, support made-in-Canada biomanufacturing and clinical trials, and training in translational research and commercialization. Read more
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.